Physician profile
William H Smith
NPI 1891769212
$810.87
in general payments reported to CMS, 2019-2025
17 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $100 · 2021: $31.56 · 2022: $71.44 · 2023: $248 · 2024: $136 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $485.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $189.43 | 2019-2021 | |
| Abbott Laboratories | $175.30 | 2020-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $91.08 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Abbvie INC. | $58.29 | 2023 | Ubrelvy, Qulipta |
| Boston Scientific Corporation | $52.03 | 2024-2025 | General - Erectile Dysfunction |
| Antares Pharma, INC. | $38.97 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Inspire Medical Systems, INC. | $30.06 | 2023 | Inspire |
| Lilly USA, LLC | $25.48 | 2024 | Zepbound |
| Daiichi Sankyo INC. | $23.91 | 2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $17.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.95 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $16.88 | 2025 | Proquad, Enflonsia, Capvaxive |
| Pfizer INC. | $16.60 | 2024 | |
| Astellas Pharma US INC | $15.76 | 2025 | Veozah |
| Novo Nordisk INC | $15.40 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alon Medical Technology | $14.67 | 2025 | |
| Vapotherm INC | $12.71 | 2023 | Vapotherm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.